[go: up one dir, main page]

USRE36594E - Spin trap nitronyl hindered phenols - Google Patents

Spin trap nitronyl hindered phenols Download PDF

Info

Publication number
USRE36594E
USRE36594E US08/942,494 US94249497A USRE36594E US RE36594 E USRE36594 E US RE36594E US 94249497 A US94249497 A US 94249497A US RE36594 E USRE36594 E US RE36594E
Authority
US
United States
Prior art keywords
tert
iaddend
iadd
butyl
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/942,494
Inventor
Edward G. Janzen
Allan L. Wilcox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Priority to US08/942,494 priority Critical patent/USRE36594E/en
Application granted granted Critical
Publication of USRE36594E publication Critical patent/USRE36594E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Definitions

  • the present invention relates to novel nitronyl substituted phenols.
  • the present invention also relates to methods using nitronyl substituted hindered phenols as antioxidants in biological systems and therapeutic applications.
  • antioxidants have been proposed for therapeutic treatment and for other uses such as protecting polymers such as natural rubber and synthetic rubber from oxidation.
  • Hindered phenols occur naturally, for example tocopherols (vitamin E), and have found use as antioxidants previously.
  • free radicals have been postulated to have significant impact in tissue injury. Evidence suggests that the free radical mechanism has a significant impact on vascular injury and damage affecting nerve cells.
  • the present invention offers the advantages of a spin trap agent with no known toxic effects. Further, the invention offers the advantage of providing compounds highly efficient in the quenching of free radicals.
  • the present invention relates to the use of particular antioxidants in therapeutic treatment.
  • These compositions have the following general formula: ##STR2## wherein R1 is a hydrogen, an aryl, or an alkyl and R2 is an alkyl or an aryl group.
  • R1 can be any alkyl group, straight chain or branched, with or without double or triple bonds, with or without polar functions (e.g., esters, alcohols, halides, carboxylic acid, aldehydes, carboxamides, aralkyl, amino or nucleic acids).
  • R2 can contain single, double or triple bonds and may also include polar constituents (e.g., esters, alcohols, halides, carboxylic acids, aldehydes, carboxamides, aralkyl, amino or nucleic acids).
  • R2 can also be an aryl including substituted aryls, heterocyclic, polycyclic or acyclic.
  • R3 and R4 can be hydrogen or any alkyl group, either straight chain or branched, preferably 1 to 4 carbons.
  • R3 and R4 are preferably alkyls from 1 to 4 carbons in length.
  • R3 and R4 are usually the same group. Based on animal studies the dosage of these compounds is in the range of 25 to 250 mg/kg. In the preferred embodiment, the range is between 25 and 125 mg/kg depending upon the dosage required to capture the free radical.
  • One or more of the above compounds useful in the present invention can be mixed together in the same dose.
  • the present invention also relates to the use of compounds of a general formula: ##STR3## Based upon animal studies, the dosage in the range of 25 to 250 mg/kg is useful. In the preferred embodiment, the range is between 25 to 125 mg/kg.
  • the present invention also relates to the use of compounds of the general formula: ##STR4## wherein R5, R6, R7, R8 and R9 are alkyl groups, and preferably R5, R6, R7, R8 and R9 are alkyls of 1 to 4 carbons. It is believed that these compounds would be useful in a dosage range of from about 25 mg to about 250 mg/kg of body weight.
  • Another aspect of the present invention relates to novel compounds of the formulas useful as spin traps in biological systems:
  • FIG. 1 is a graphical representation of inhibitor concentration for 50% inhibition (IC 50 ) using rat liver microsomes wherein LPO (liquid peroxidation) was initiated by tert butoxyl radicals and MDA (malondialdehyde) production was monitored by treatment with thiobarbituric acid;
  • LPO liquid peroxidation
  • MDA malondialdehyde
  • FIG. 2 is a graphical representation of inhibitor concentration for 50% inhibition (IC 50 ) using rat liver microsomes where LPO is initiated by NADPH catalyzed cytochrome-P450 metabolism of CCl 4 based on the TBA (thiobarbituric acid) test for MDA production; and
  • FIG. 3 is a graphical representation of inhibitor concentration for 50% inhibition (IC 50 ) of LPO for rat brain microsomes using the TBA test for MDA production.
  • a free radical scavenger or spin trap reagent is a molecule which will form a stable complex with a free radical.
  • a carbon centered free radical is a molecule in which the free radical is localized on a carbon atom. As result of this chemical bond formation with a spin trap, the free radical is no longer damaging to cells.
  • phenoxyl radicals which are stabilized by steric hinderance due to groups at the 2-and 6-position have an added advantage that they persist long enough to trap other radicals thereby quenching two radicals.
  • 2,6-di-tert-butyl phenols produce 2,6-di-tert-butyl phenoxyl radicals which are stabilized due to the steric hinderance of the tert-butyl groups.
  • the hindered phenoxyl has the advantage that they persist long enough to trap other radicals. ##
  • the rate of the first reaction depends upon the concentration of phenol and free radical.
  • the rate of the first reaction is the first reaction rate constant times the concentration of the phenol times the concentration of free radicals.
  • the rate of the second reaction depends on the concentration of the hindered phenoxyl and concentration of free radical.
  • the reaction rate of the second reaction is the value of the second reaction rate constant, times the concentration of phenoxyl times the concentration of free radical.
  • the appropriate choice of the substituent in the 4-position (Y) can increase the lifetime of the hindered phenoxyl radical produced.
  • the groups in the 4-position which stabilize the hindered phenoxyl radicals also reduce the reaction rate of the radical with oxygen thereby preventing formation of potentially damaging peroxyl radicals. For example: ##STR11##
  • the reaction with oxygen at the 4-position can be hindered by several methods. For example, steric hinderance may be utilized, and generally, the reaction is slowed but not entirely eliminated. ##STR12##
  • Another method is to provide resonance with the carbon in the 4-position.
  • a completely stable phenoxyl radical is obtained.
  • groups capable of strong resonance with the phenoxyl function stabilize the phenoxyl radical and prevent an addition reaction with oxygen.
  • Another method of stabilization is the addition of a strained ring or rings within the phenoxyl radical adduct.
  • Y is a phenoxyl ring such as ⁇ -tocophenoxyl addition of oxygen is not favored.
  • the strained bicyclic ring structure in the peroxyl radical is a high energy product, and the formation of the peroxyl from oxygen is very unfavorable.
  • phenoxyl radicals with strained rings can be beneficial because although they will not readily react with oxygen radicals, reactions may proceed with other peroxyl radicals to form stable adducts.
  • R1 is hydrogen, an aryl, or an alkyl
  • R2 is an alkyl or an aryl.
  • the alkyls of R1 and R2 can contain single, double or triple bonds and can also include polar constituents like esters, alcohol, halides, carboxylic acids, aldehydes, carboxamides, aralkyl amino or nucleic acids and others.
  • R1 and R2 can also be an aryl including substituted aryls, heterocyclic, polycyclic or acyclic.
  • R3 and R4 can be any alkyl group, either straight chained or branched.
  • R3 and R4 are alkyls from 1 to 4 carbons in length. In the preferred embodiment, R3 and R4 are the same group because synthesis of such compounds is typically easier than when R3 and R4 are different.
  • 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol DBBNP: ##STR17## or 2,6-di-tert-butyl-4-(N-tert-octyl) nitronyl phenol (DBONP): ##STR18## are employed in a method for quenching biological free radicals. Less preferred compounds for said method include 2,6-dimethyl-4-(N-tert-octyl) nitronyl phenol (DMONP): ##STR19## and 2,6-dimethyl-4-(N-tert-butyl) nitronyl phenol (DMBNP): ##STR20##
  • N-tert-octyl C-phenyl nitrone OPN
  • Spin traps have been implicated as useful in a number of diseases including septic shock, effect of ischemia/reperfusion, liver edema, and fatigue stress.
  • the spin trapping efficiency is believed to be associated with not only the molecular configuration but also the relative size of the molecule in respect to the particular disease sought to be prevented or treated.
  • certain spin trap compounds may be more effective with certain diseases than other spin trap compounds.
  • Spin trap compounds of the present invention were placed in pharmaceutical vehicles suitable for administration to a patient, preferably in a fat soluble substance for oral administration.
  • the spin trap compounds of the present invention are useful in preventing or reversing edema.
  • the compositions can also contain other active agents, such as buffering agents such as antacids or inert carriers such as lactose.
  • the examples demonstrate the utility of the compounds of the present invention in preventing or treating a variety of inflammation effects.
  • Exemplary doses range from 25 to 250 mg of compound/kg of body weight in animals.
  • the more preferred range of dosage is from about 25 to about 125 mg/kg.
  • the effective range of dosage in humans and other mammals is expected to be between about 25 to about 50 mg/kg, and preferably between about 25 to about 35 mg/kg of body weight.
  • the particular dosage may vary depending on the particular compound selected and the disease to be treated. Those compounds which are more effective will require a smaller dosage than those compounds which have been found to be less effective.
  • the most preferred ranges are expected to be (a) from about 25 to about 35 mg/kg for DBBNP; (b) from about 25 to about 35 mg/kg body weight for DBONP; (c) from about 25 to about 35 mg/kg of body weight for DMONP; (d) from about 25 to about 35 mg/kg of body weight for DMBNP; and (e) from about 25 to about 35 mg/kg of body weight for OPN.
  • R5, R6, R7, R8 and R9 are alkyl groups, and preferably alkyl groups of 1 to 4 carbon atoms. These compounds are expected to be useful in dosages from 25 to 250 mg/kg of body weight, preferably 25 to 125 mg/kg and more preferably from about 25 to about 50 mg/kg of body weight.
  • the compounds of the present invention are preferably administered systemically, most preferably orally, since this is the most rapid and efficient means for delivering the active compound to the site of free radical generation.
  • the compounds can be administered at once, or can be divided into a number of smaller doses to be administered at varying intervals of times.
  • the compounds may also be administered by other methods including intravenous, subcutaneous, topical, and intraperitoneal administration.
  • a preferred method of administration of the compounds of the present invention is oral delivery.
  • the compounds may be enclosed in capsules, compressed into tablets, microencapsulated, entrapped in liposomes, in solution or suspension, alone or in combination with a substrate immobilizing material such as starch or poorly absorbable salts.
  • a substrate immobilizing material such as starch or poorly absorbable salts.
  • Pharmaceutically compatible binding agents and/or adjuvant materials can be used as part of a composition.
  • Tablets or capsules can contain any of the following ingredients, or compounds of similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; an integrating agent such as alginic acid, CrimogelTM, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; and sweetening and flavoring agents.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose
  • an integrating agent such as alginic acid, CrimogelTM, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • sweetening and flavoring agents When a capsule form is used the liquid carrier such as a fatty oil may be used.
  • Capsules and tablets can be coated with
  • the present invention will be further understood by reference to the following nonlimiting examples demonstrating methods for determining the effectiveness of the compounds of the present invention for the treatment or prevention of inflammation effects, septic shock, effects of ischemia/reperfusion, liver edema, fatigue stress.
  • EPR samples from the in vivo experiments were run on a Bruker 300E Electron Paramagnetic Resonance Spectrophotometer. Two milliliters of sample were placed in a quartz tube of 2 mm inside diameter. EPR parameters were as follows with the exception of the receiver gain and scale. These are adjusted for each sample to get the best signal.
  • Microsomes were prepared by homogenizing the minced livers in 0.15 M potassium phosphate buffer pH 7.4 5 ml/g) and then centrifuging at 12,000 ⁇ g for 15 minutes. The supernatant fraction was then centrifuged at 105,000 ⁇ g for 90 minutes. The microsomal pellets were washed twice by resuspending in buffer and centrifuging at 105,000 ⁇ g for 60 minutes. The microsomal pellets were kept frozen at -80° C. until ready for use.
  • Rat liver microsome pellets were made up into microsomal suspension (MS) by adding one milliliter of 50 mM potassium phosphate buffer (pH 7.4) per gram of liver.
  • the protein concentration of microsomal suspensions were determined by the method of O. H. Lowry et al., J. Biol. Chem. 193:265-75 (1951).
  • Reaction samples were 1 ml (milliliter) in volume and consisted of MS (0.1 ml), 50 mM potassium phosphate buffer (KH 2 PO 4 and K 2 HPO 4 ) (pH 7.4), inhibitor in alcohol (isopropyl) and initiator (DBPO) in isopropyl alcohol.
  • the order of addition of reagents was buffer, MS, inhibitor and finally initiator.
  • the reaction components were: buffer (as above), 1 mM EDTA, MS, CCl 4 (100 mM) and generating system.
  • the generating system consisted of 0.5 Kornberg units of glucose-6-phosphate dehydrogenase, 5 ⁇ M glucose-6-phosphate and 0.3 mM NADPH. After all reagents were added, the test tubes were vortexed and placed in a 37° C. shaking water bath. Samples were incubated for one hour. A. Ottolenghi, Arch. Biochem. Biophs. 79:355 (1959). The lipid peroxidation (LPO) reaction was stopped by the addition of 0.5 ml 35% TCA (trichloroacetic acid) (weight/volume in distilled H 2 O) and 1.0 ml 0.5% TBA (thiobarbituric acid) (w/v in distilled H 2 O).
  • TCA trichloroacetic acid
  • TBA thiobarbituric acid
  • IC 50 was attempted to be reached by trial and error. In the event it was missed, the IC 50 value was determined by interpolation of the results. Interpolations were made using the closest result higher than IC 50 and the closest result lower than IC 50 . The reference to "measured" means that IC 50 was hit right on and thus no interpolation was required.
  • DBBNP is about 2000 times more effective as an inhibitor of LPO in rat liver microsomes than PBN and about 20% better than BHT. Even taking into account experimental precision, one can conclude that DBBNP is at least as good as BHT and probably better.
  • FIG. 1 is a graphical representation of inhibitor concentration for 50% inhibition (IC 50 ) using rat liver microsomes wherein LPO (liquid peroxidation) was initiated by tert-butoxyl radicals and MDA (malondialdehyde) production was monitored by treatment with thiobarbituric acid (TBA). The relative effectiveness between the compounds can be seen, with the smaller bars indicating better performance.
  • LPO liquid peroxidation
  • MDA malondialdehyde
  • FIG. 2 is a graphical representation of inhibitor concentration for 50% inhibition (IC 50 ) using rat liver microsomes where LPO is initiated by NADPH catalyzed cytochrome-P450 metabolism of CCl 4 based on the TBA (thiobarbituric acid) test for MDA production.
  • FIG. 3 is a graphical representation of inhibitor concentration for 50% inhibition (IC 50 ) of LPO for rat brain microsomes using the TBA test for MDA production.
  • 2-Methyl-2-nitropropane was prepared as follows: potassium permanganate (650 g, 4.1 mole) was dissolved in 3 L H 2 O and t-butyl amine (100 g, 1.4 mole) added over 30 minutes. The temperature was brought to 90° C. and the reaction allowed to cool for 4 hours with stirring by mechanical stirrer. A still head and condensor was attached to a side arm of the 5 L three neck round bottom flask and the product distilled off. Diethyl ether was added and the product washed 2 ⁇ with 5% HCl, 1 ⁇ with H 2 O, 1 ⁇ with saturated NaCl. The organic layer was dried over MgSO 4 and the solvent stripped leaving 112.6 g (1.09 mole, 78%) clear liquid.
  • 4-Nitro-2,2,4-trimethylpentane was prepared as follows: potassium permanganate (380 g, 2.4 mole) was added in portions to t-octyl amine (50 g, 0.4 mole) and MgSO 4 ⁇ 7H 2 O (60 g) in 250 mL H 2 O with mechanical stirring. The temperature was maintained below 30° C. with an ice bath. Stirring and cooling was continued for 2.5 hours after which the reaction was allowed to warm to room temperature and stirred for 48 hours. The reaction was filtered and the residue washed with pentane. The organic layer was separated, dried over MgSO 4 and pentane distilled at atmospheric pressure. The product was distilled at ⁇ 1 mm to give 30 g (47%) of clear liquid.
  • t-Octyl hydroxylamine was prepared as follows: 4-nitro-2,2,4-trimethylpentane (10.35 g, 0.065 mole) with NH 4 Cl (3.49 g, 0.065 mole) was cooled in 75% THF/H 2 O with stirring by a magnetic stir bar to 10° C. and zinc (25.5 g, 0.39 mole) added in portions to maintain the temperature at 10°-15° C. (one hour). Reaction was allowed to warm to room temperature and stirred for one hour. The mixture was filtered and the solvent stripped leaving 9.25 g (98%) clear liquid. The hydroxylamine was used immediately in subsequent reactions.
  • 2,6-di-tert-butyl-4-(N-tert-octyl) nitronyl phenol can be prepared as follows. t-Octyl hydroylamine and 3,5-di-tert-butyl-4-hydroxybenzaldehyde are refluxed in benzene with p-TsOH for sufficient time to begin the reaction. t-Octyl hydroylamine can then be added and the reaction stirred until complete reaction has occurred. The solvent is then stripped, the residue applied to a silica gel column, and product eluted with mixtures of hexane/EtOAc which should produce DBONP crystals with a melting point of 153°-154° C.
  • N-tert-octyl C-phenyl nitrone can be prepared as follows: t-octyl hydroxylamine and 4-hydroxybenzaldehyde should be refluxed in benzene with p-TsOH for sufficient time to begin the reaction. Additional t-octyl hydroxylamine can be added and the reactants stirred until completion of the reaction. The solvent can then be stripped, the residue applied to silica gel column and product eluted with mixture of hexane/EtOAc which should give OPN crystals.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is the use of nitronyl substituted hindered phenols as antioxidants in therapeutic applications. In the preferred embodiment the compositions have the general formula: Wherein R1 is hydrogen, an alkyl or an aryl and R2 is an alkyl or an aryl; R3 is an alkyl; and R4 is an alkyl. Further, the invention relates to novel compositions useful as antioxidants. The novel compounds include: 2,6-di-tert-butyl-4-(N-tert-octyl)nitronyl phenol (DBONP); 2,6-dimethyl-4-(N-tert-octyl)nitronyl phenol (DMONP); N-tert-octyl-C-phenyl nitrone (OPN).

Description

TECHNICAL FIELD OF THE INVENTION
The present invention relates to novel nitronyl substituted phenols. The present invention also relates to methods using nitronyl substituted hindered phenols as antioxidants in biological systems and therapeutic applications.
BACKGROUND OF THE INVENTION
The use of antioxidants has been proposed for therapeutic treatment and for other uses such as protecting polymers such as natural rubber and synthetic rubber from oxidation. Hindered phenols occur naturally, for example tocopherols (vitamin E), and have found use as antioxidants previously. Recently, free radicals have been postulated to have significant impact in tissue injury. Evidence suggests that the free radical mechanism has a significant impact on vascular injury and damage affecting nerve cells.
The use of phenylbutyl nitrone compositions for the treatment of oxidative tissue damage and gastric ulceration has been disclosed in U.S. Pat. Nos. 5,025,032 and 5,036,097 entitled "Phenylbutyl Nitrone Compositions and Methods For Treatment of Oxidative Tissue Damage" and "Phenylbutyl Nitrone Compositions and Methods for Prevention of Gastric Ulceration", respectively.
Research has demonstrated that nitrones select a location in membrane models and microsomes which is as polar and/or as protic as pure methanol as discussed in E. G. Janzen et al., "Locating spin traps in heterogeneous media by 13 C NMR spectroscopy. Investigations in SDS micelles, DMPC vesicles and rat liver microsomes", J. Org. Chem. 54:2915-2920 (1989). Thus, it is suggested that antioxidant molecules must be precisely located in the same volume compartment as where the free radical event occurs, or else the free radicals will not be quenched. Heretofore, such molecules have not been available. Therefore, development of new families of antioxidant molecules is necessary in order to provide molecules which will be effective against free radical damage at different biological sites. There has also been a need to provide antioxidant compositions which have no known toxic effect while providing a more effective free radical spin trap.
The present invention offers the advantages of a spin trap agent with no known toxic effects. Further, the invention offers the advantage of providing compounds highly efficient in the quenching of free radicals.
SUMMARY OF THE INVENTION
The present invention relates to the use of particular antioxidants in therapeutic treatment. These compositions have the following general formula: ##STR2## wherein R1 is a hydrogen, an aryl, or an alkyl and R2 is an alkyl or an aryl group. R1 can be any alkyl group, straight chain or branched, with or without double or triple bonds, with or without polar functions (e.g., esters, alcohols, halides, carboxylic acid, aldehydes, carboxamides, aralkyl, amino or nucleic acids). R2 can contain single, double or triple bonds and may also include polar constituents (e.g., esters, alcohols, halides, carboxylic acids, aldehydes, carboxamides, aralkyl, amino or nucleic acids). R2 can also be an aryl including substituted aryls, heterocyclic, polycyclic or acyclic. R3 and R4 can be hydrogen or any alkyl group, either straight chain or branched, preferably 1 to 4 carbons. R3 and R4 are preferably alkyls from 1 to 4 carbons in length. R3 and R4 are usually the same group. Based on animal studies the dosage of these compounds is in the range of 25 to 250 mg/kg. In the preferred embodiment, the range is between 25 and 125 mg/kg depending upon the dosage required to capture the free radical. One or more of the above compounds useful in the present invention can be mixed together in the same dose.
The present invention also relates to the use of compounds of a general formula: ##STR3## Based upon animal studies, the dosage in the range of 25 to 250 mg/kg is useful. In the preferred embodiment, the range is between 25 to 125 mg/kg.
The present invention also relates to the use of compounds of the general formula: ##STR4## wherein R5, R6, R7, R8 and R9 are alkyl groups, and preferably R5, R6, R7, R8 and R9 are alkyls of 1 to 4 carbons. It is believed that these compounds would be useful in a dosage range of from about 25 mg to about 250 mg/kg of body weight.
Another aspect of the present invention relates to novel compounds of the formulas useful as spin traps in biological systems:
(a) N-tert-octyl C-phenyl nitrone ("OPN") ##STR5## (b) 2,6-di-tert-butyl-4-(N-tert-octyl) nitronyl phenol ("DBONP") ##STR6## (c) 2,6-dimethyl-4-(N-tert-octyl) nitronyl phenol ("DMONP") ##STR7## and (d) compounds of the general formula ##STR8## wherein R10 is an alkyl 8 or more carbons in length. Such compounds are to be used in the method of the present invention in a dosage from 25 to 250 mg/kg, preferably from about 25 to 125 mg/kg, and more preferably from about 25 to about 50 mg/kg.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will be more fully appreciated from the following description taken in conjunction with the accompanying drawings, in which:
FIG. 1 is a graphical representation of inhibitor concentration for 50% inhibition (IC50) using rat liver microsomes wherein LPO (liquid peroxidation) was initiated by tert butoxyl radicals and MDA (malondialdehyde) production was monitored by treatment with thiobarbituric acid;
FIG. 2 is a graphical representation of inhibitor concentration for 50% inhibition (IC50) using rat liver microsomes where LPO is initiated by NADPH catalyzed cytochrome-P450 metabolism of CCl4 based on the TBA (thiobarbituric acid) test for MDA production; and
FIG. 3 is a graphical representation of inhibitor concentration for 50% inhibition (IC50) of LPO for rat brain microsomes using the TBA test for MDA production.
DETAILED DESCRIPTION OF THE INVENTION
As used herein a free radical scavenger or spin trap reagent (compound) is a molecule which will form a stable complex with a free radical. A carbon centered free radical is a molecule in which the free radical is localized on a carbon atom. As result of this chemical bond formation with a spin trap, the free radical is no longer damaging to cells.
Antioxidant activity has been long studied in lubricating oils by the automobile industry. The general principles and mechanisms from the lubricating oil studies has been accepted for lipid peroxidation in tissue membranes. In addition, without being bound to any particular theory we believe that there are some specific considerations which are specific to biological systems. Reactive radicals which can be damaging to tissue constituents are easily quenched by the phenolic hydrogen which is easily removed by most free radicals. ##STR9## This reaction produces non-damaging radicals, that is radicals that are resonance stabilized and have little reactivity. The phenoxyl radicals, in general, have been observed to disappear without creating obvious biological damage.
It has been found in biological systems that phenoxyl radicals which are stabilized by steric hinderance due to groups at the 2-and 6-position have an added advantage that they persist long enough to trap other radicals thereby quenching two radicals. For example, it has been found that 2,6-di-tert-butyl phenols produce 2,6-di-tert-butyl phenoxyl radicals which are stabilized due to the steric hinderance of the tert-butyl groups. The hindered phenoxyl has the advantage that they persist long enough to trap other radicals. ##STR10##
To increase the efficiency of the antioxidant activity and achieve maximum potential, it is desirable to utilize a compound which produces a high concentration of the hindered phenoxyl which will be available to capture the additional free radicals.
It is preferred that the compounds used in the present application have a reasonably long lifetime to increase efficiency. The rate of the first reaction depends upon the concentration of phenol and free radical. The rate of the first reaction is the first reaction rate constant times the concentration of the phenol times the concentration of free radicals. The rate of the second reaction depends on the concentration of the hindered phenoxyl and concentration of free radical. The reaction rate of the second reaction is the value of the second reaction rate constant, times the concentration of phenoxyl times the concentration of free radical. Thus, it is beneficial to use compounds which result in maximum concentration of phenoxyl.
The appropriate choice of the substituent in the 4-position (Y) can increase the lifetime of the hindered phenoxyl radical produced. The groups in the 4-position which stabilize the hindered phenoxyl radicals also reduce the reaction rate of the radical with oxygen thereby preventing formation of potentially damaging peroxyl radicals. For example: ##STR11##
The reaction with oxygen at the 4-position can be hindered by several methods. For example, steric hinderance may be utilized, and generally, the reaction is slowed but not entirely eliminated. ##STR12##
Another method is to provide resonance with the carbon in the 4-position. When the ethylenic bond is obtained, a completely stable phenoxyl radical is obtained. Thus, groups capable of strong resonance with the phenoxyl function stabilize the phenoxyl radical and prevent an addition reaction with oxygen. ##STR13##
Another method of stabilization is the addition of a strained ring or rings within the phenoxyl radical adduct. Thus, when Y is a phenoxyl ring such as α-tocophenoxyl addition of oxygen is not favored. It is believed that the strained bicyclic ring structure in the peroxyl radical is a high energy product, and the formation of the peroxyl from oxygen is very unfavorable. ##STR14## These phenoxyl radicals with strained rings can be beneficial because although they will not readily react with oxygen radicals, reactions may proceed with other peroxyl radicals to form stable adducts.
Compounds which are useful in the present invention have the following general formula: ##STR15## where R1 is hydrogen, an aryl, or an alkyl and R2 is an alkyl or an aryl. The alkyls of R1 and R2 can contain single, double or triple bonds and can also include polar constituents like esters, alcohol, halides, carboxylic acids, aldehydes, carboxamides, aralkyl amino or nucleic acids and others. R1 and R2 can also be an aryl including substituted aryls, heterocyclic, polycyclic or acyclic. R3 and R4 can be any alkyl group, either straight chained or branched. Preferably, R3 and R4 are alkyls from 1 to 4 carbons in length. In the preferred embodiment, R3 and R4 are the same group because synthesis of such compounds is typically easier than when R3 and R4 are different.
Other compounds useful in the present invention and which are novel compounds have the general formula: ##STR16## wherein in R10 is an alkyl of 8 or more carbons.
Preferably, 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol (DBBNP): ##STR17## or 2,6-di-tert-butyl-4-(N-tert-octyl) nitronyl phenol (DBONP): ##STR18## are employed in a method for quenching biological free radicals. Less preferred compounds for said method include 2,6-dimethyl-4-(N-tert-octyl) nitronyl phenol (DMONP): ##STR19## and 2,6-dimethyl-4-(N-tert-butyl) nitronyl phenol (DMBNP): ##STR20##
Another novel compound useful in the present invention is N-tert-octyl C-phenyl nitrone (OPN) which is represented below. ##STR21##
Spin traps have been implicated as useful in a number of diseases including septic shock, effect of ischemia/reperfusion, liver edema, and fatigue stress. The spin trapping efficiency is believed to be associated with not only the molecular configuration but also the relative size of the molecule in respect to the particular disease sought to be prevented or treated. Thus, certain spin trap compounds may be more effective with certain diseases than other spin trap compounds.
Spin trap compounds of the present invention were placed in pharmaceutical vehicles suitable for administration to a patient, preferably in a fat soluble substance for oral administration. The spin trap compounds of the present invention are useful in preventing or reversing edema. The compositions can also contain other active agents, such as buffering agents such as antacids or inert carriers such as lactose.
The examples demonstrate the utility of the compounds of the present invention in preventing or treating a variety of inflammation effects. Exemplary doses range from 25 to 250 mg of compound/kg of body weight in animals. The more preferred range of dosage is from about 25 to about 125 mg/kg. The effective range of dosage in humans and other mammals is expected to be between about 25 to about 50 mg/kg, and preferably between about 25 to about 35 mg/kg of body weight. The particular dosage may vary depending on the particular compound selected and the disease to be treated. Those compounds which are more effective will require a smaller dosage than those compounds which have been found to be less effective. For preferred embodiments of the invention, the effective range of dosage in humans and other mammals is expected to be in the range of: (a) from about 25 to about 50 mg/kg for DBBNP; (b) from about 25 to about 50 mg/kg body weight for DBONP; (c) from about 25 to about 50 mg/kg of body weight for DMONP; (d) from about 25 to about 50 mg/kg of body weight for DMBNP; and (e) from about 25 to about 50 mg/kg of body weight for OPN. The most preferred ranges are expected to be (a) from about 25 to about 35 mg/kg for DBBNP; (b) from about 25 to about 35 mg/kg body weight for DBONP; (c) from about 25 to about 35 mg/kg of body weight for DMONP; (d) from about 25 to about 35 mg/kg of body weight for DMBNP; and (e) from about 25 to about 35 mg/kg of body weight for OPN.
Other compounds believed to be useful include compounds of the general formula: ##STR22## wherein R5, R6, R7, R8 and R9 are alkyl groups, and preferably alkyl groups of 1 to 4 carbon atoms. These compounds are expected to be useful in dosages from 25 to 250 mg/kg of body weight, preferably 25 to 125 mg/kg and more preferably from about 25 to about 50 mg/kg of body weight.
The compounds of the present invention are preferably administered systemically, most preferably orally, since this is the most rapid and efficient means for delivering the active compound to the site of free radical generation. The compounds can be administered at once, or can be divided into a number of smaller doses to be administered at varying intervals of times. The compounds may also be administered by other methods including intravenous, subcutaneous, topical, and intraperitoneal administration.
A preferred method of administration of the compounds of the present invention is oral delivery. The compounds may be enclosed in capsules, compressed into tablets, microencapsulated, entrapped in liposomes, in solution or suspension, alone or in combination with a substrate immobilizing material such as starch or poorly absorbable salts. Pharmaceutically compatible binding agents and/or adjuvant materials can be used as part of a composition. Tablets or capsules can contain any of the following ingredients, or compounds of similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; an integrating agent such as alginic acid, Crimogel™, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; and sweetening and flavoring agents. When a capsule form is used the liquid carrier such as a fatty oil may be used. Capsules and tablets can be coated with sugar, shellac and other enteric agents as is known.
The present invention will be further understood by reference to the following nonlimiting examples demonstrating methods for determining the effectiveness of the compounds of the present invention for the treatment or prevention of inflammation effects, septic shock, effects of ischemia/reperfusion, liver edema, fatigue stress.
Compounds useful in the method present of the present invention were compared against
(a) butylated hydroxy toulene ("BHT") ##STR23## (b) α-phenyl t-butyl nitrone ("PBN") ##STR24## and (c) α-tocopherol (Vitamin E).
Inhibition of lipid peroxidation of rat liver microsomes has been found to be remarkably effective utilizing 4-nitronyl hindered phenols. The efficiency of these compounds was compared to the inhibition characteristics of a hindered phenol antioxidant, butylated hydroxy toluene (BHT) and α-phenyl t-butyl nitrone (PBN). Comparisons were also made with compounds useful in the present invention as well as the novel compounds of the present invention 2,6-di-tert-butyl-4-(N-tert-octyl) nitronyl phenol (DBONP); 2,6-dimethyl-4-(N-tert-octyl) nitronyl phenol (DMONP); and N-tert-octyl-C-phenyl nitrone (OPN).
EPR samples from the in vivo experiments were run on a Bruker 300E Electron Paramagnetic Resonance Spectrophotometer. Two milliliters of sample were placed in a quartz tube of 2 mm inside diameter. EPR parameters were as follows with the exception of the receiver gain and scale. These are adjusted for each sample to get the best signal.
______________________________________                                    
Receiver          Signal Channel                                          
Receiver Gain                                                             
          1.00 e + 05 Conversion                                          
                                327.68 ms                                 
Phase     0 deg       Time Const                                          
                                1310.72 ms                                
Harmonic  1           Sweep Time                                          
                                335.544 ms                                
Mod. Frequency                                                            
          100.0000 kHz                                                    
                      Scale     18                                        
Field             Microwave                                               
Center Field                                                              
          3480.01 G   Frequency 9.77 GHz                                  
Sweep Width                                                               
          100.00 G    Power     1.99 e + 01 mW                            
Resolution                                                                
          1024 points                                                     
______________________________________
Example 1
Lipid peroxidation (LPO) initiated by tert-butoxy radicals
Male Sprague-Dawley rats (175-200 g) that had been maintained on commercial rat chow were starved for 24 hours, sacrificed and the livers removed. Microsomes were prepared by homogenizing the minced livers in 0.15 M potassium phosphate buffer pH 7.4 5 ml/g) and then centrifuging at 12,000×g for 15 minutes. The supernatant fraction was then centrifuged at 105,000×g for 90 minutes. The microsomal pellets were washed twice by resuspending in buffer and centrifuging at 105,000×g for 60 minutes. The microsomal pellets were kept frozen at -80° C. until ready for use. Rat liver microsome pellets were made up into microsomal suspension (MS) by adding one milliliter of 50 mM potassium phosphate buffer (pH 7.4) per gram of liver. The protein concentration of microsomal suspensions were determined by the method of O. H. Lowry et al., J. Biol. Chem. 193:265-75 (1951).
Reaction samples were 1 ml (milliliter) in volume and consisted of MS (0.1 ml), 50 mM potassium phosphate buffer (KH2 PO4 and K2 HPO4) (pH 7.4), inhibitor in alcohol (isopropyl) and initiator (DBPO) in isopropyl alcohol. The order of addition of reagents was buffer, MS, inhibitor and finally initiator. For those experiments where the NADPH generating system is used as initiator, the reaction components were: buffer (as above), 1 mM EDTA, MS, CCl4 (100 mM) and generating system. The generating system consisted of 0.5 Kornberg units of glucose-6-phosphate dehydrogenase, 5 μM glucose-6-phosphate and 0.3 mM NADPH. After all reagents were added, the test tubes were vortexed and placed in a 37° C. shaking water bath. Samples were incubated for one hour. A. Ottolenghi, Arch. Biochem. Biophs. 79:355 (1959). The lipid peroxidation (LPO) reaction was stopped by the addition of 0.5 ml 35% TCA (trichloroacetic acid) (weight/volume in distilled H2 O) and 1.0 ml 0.5% TBA (thiobarbituric acid) (w/v in distilled H2 O). Samples were capped with glass marbles and placed in a boiling (100° C.) water bath for 15 minutes, then cooled rapidly in an ice bath. One milliliter of distilled H2 O and 2 ml chloroform were added, samples vortexed and then centrifuged at 1500 rpm for 10 minutes. The aqueous layer was read at 532 nm on a Perkin-Elmer Lambda UV/VIS spectrophotometer using a distilled H2 O blank. MDA (malondialdehyde) calculations were made by the following equation: ##EQU1##
Inhibition studies were performed by doing a concentration course of the inhibitor added to the LPO system. A stock solution of the inhibitor was made up so that various dilutions would give several (usually five) final concentrations. The original concentrated stock was usually 1M (molar) and dilutions were made to give the following final concentrations: 10, 1, 0.1, and 0.01 mM. Control samples had no inhibitor. Five samples were done for each concentration. After MDA values were calculated, percent of inhibition was determined by: average of MDA values for a given concentration divided by average of MDA values for control multiplied by 100. These results then determined if further dilutions were necessary to achieve a 50% inhibition of LPO.
______________________________________                                    
Inhibition Concentration of 50% Inhibition (IC.sub.50)                    
(average of 5 experiments)                                                
______________________________________                                    
BHT          5.3 μM (interpolated between 5 and 6 μM)               
PBN        9800 μM (interpolated between 5 and 10 mM)                  
DBBNP        4.3 μM (interpolated between 2.5 and 5 μM)             
DBONP        5.8 μM (interpolated between 5 and 7.5 μM)             
DMONP       16.4 μM (interpolated between 15 and 20 μM)             
DMBNP       230 μM (estimated from 250 μM experiment)               
OPN         462 μM (estimated from 250 and 500 μM)                  
Tocopherol  30 μM (measured)                                           
(vitamin E)                                                               
______________________________________
In this example and the following examples, IC50 was attempted to be reached by trial and error. In the event it was missed, the IC50 value was determined by interpolation of the results. Interpolations were made using the closest result higher than IC50 and the closest result lower than IC50. The reference to "measured" means that IC50 was hit right on and thus no interpolation was required.
The test results demonstrate that the flanking tert-butyl groups in the ortho positions (2, 6) of the phenol give improved efficiency. The relative efficiency of the various compounds from the above data normalized to 1.0 for PBN can be represented as follows:
__________________________________________________________________________
DBBNP>                                                                    
     BHT>                                                                 
         DBONP>                                                           
              DMONP>                                                      
                   Vit E>                                                 
                        VMBNP>                                            
                             OPN>                                         
                                 PBN                                      
__________________________________________________________________________
2466 2000                                                                 
         1828 646  354  46   24  1.0                                      
__________________________________________________________________________
Thus, DBBNP is about 2000 times more effective as an inhibitor of LPO in rat liver microsomes than PBN and about 20% better than BHT. Even taking into account experimental precision, one can conclude that DBBNP is at least as good as BHT and probably better.
Example 2
LPO initiated by NADPH catalyzed cytochrome-P450 metabolism of CCl4
An amount equal to 0.09 mmole spin trap was weighed into a test-tube to give a final concentration of 30 mM. To this container was added 14 μl 13 CCL4 (to produce a final concentration of 50 mM). After shaking to dissolve the spin trap, 2.35 ml of 50 mM potassium phosphate buffer at pH 7.4 (KH2 PO4 and K2 HPO4) was added plus 0.3 ml microsomal suspension. The solution was vortexed and preincubated for 10 minutes at room temperature (25° C.). At this point, 0.3 ml NADPH generating system (0.5 Kornberg units of glucose-6-phosphate dehydrogenase, 5 μM glucose-6-phosphate and 0.3 mM NADPH) was added to start the reaction. After incubation for 15 min at room temperature, 1.0 ml toluene was added and the system vortexed. Following centrifugation for 30 minutes at 3000 rpm (Sorvell GLC-4 with swinging bucket rotor H1000) approximately 500 μl supernatant solution is removed and transferred to an EPR quartz tube. The solution was degassed for 10 minutes with argon and scanned by EPR spectrometry.
The following results were obtained:
______________________________________                                    
Inhibitor Concentration of 50% Inhibition (IC.sub.50)                     
(average of 5 experiments)                                                
______________________________________                                    
BHT           55 μM (interpolated between 50 and 100 μM)            
PBN        17,500 μM (interpolated between 10 and 25 mM)               
DBBNP         53 μM (interpolated between 50 and 100 μM)            
DBONP         35 μM (interpolated between 20 and 40 μM)             
DMBNP        710 μM (interpolated between 500 and 750 μM)           
DMONP         60 μM (interpolated between 40 and 80 μM)             
OPN          6500 μM (interpolated between 4 and 8 mM)                 
______________________________________
Example 3
Rat Brain Miocrosomes
Similar tests were performed with rat brain microsomes using the TBA test for MDA production as the result of LPO. Results on the same compounds were as follows:
______________________________________                                    
Inhibitor Concentration for 50% Inhibition (IC.sub.50)                    
______________________________________                                    
BHT           (not available)                                             
PBN           1000 μM                                                  
DBBNP         0.7 μM                                                   
DBONP         0.3 μM                                                   
DMONP          70 μM                                                   
DMBNP         600 μM                                                   
ON             76 μM                                                   
______________________________________
Although BHT was not available for this test it is not believed that it would be particularly effective with this particular system.
The data obtained demonstrates that DBBNP and DBONP are very good inhibitors in these systems.
______________________________________                                    
IC.sub.50                                                                 
RLM (I)         RLM (II) RBM (III)                                        
______________________________________                                    
DBBNP   4.3 μM   53 μM 0.7 μM (700 nM)                           
DBONP   5.8 μM   35 μM 0.3 μM (300 mM)                           
______________________________________
The above data in Examples 1, 2 and 3 are graphically represented, respectively, in FIGS. 1, 2 and 3. It should be noted that in these graphs the smaller result is better.
FIG. 1 is a graphical representation of inhibitor concentration for 50% inhibition (IC50) using rat liver microsomes wherein LPO (liquid peroxidation) was initiated by tert-butoxyl radicals and MDA (malondialdehyde) production was monitored by treatment with thiobarbituric acid (TBA). The relative effectiveness between the compounds can be seen, with the smaller bars indicating better performance.
FIG. 2 is a graphical representation of inhibitor concentration for 50% inhibition (IC50) using rat liver microsomes where LPO is initiated by NADPH catalyzed cytochrome-P450 metabolism of CCl4 based on the TBA (thiobarbituric acid) test for MDA production.
FIG. 3 is a graphical representation of inhibitor concentration for 50% inhibition (IC50) of LPO for rat brain microsomes using the TBA test for MDA production.
SYNTHESIS OF NOVEL COMPOUNDS
Synthesis of the novel compounds of the present invention were carried out following the general procedures below.
2-Methyl-2-nitropropane was prepared as follows: potassium permanganate (650 g, 4.1 mole) was dissolved in 3 L H2 O and t-butyl amine (100 g, 1.4 mole) added over 30 minutes. The temperature was brought to 90° C. and the reaction allowed to cool for 4 hours with stirring by mechanical stirrer. A still head and condensor was attached to a side arm of the 5 L three neck round bottom flask and the product distilled off. Diethyl ether was added and the product washed 2× with 5% HCl, 1× with H2 O, 1× with saturated NaCl. The organic layer was dried over MgSO4 and the solvent stripped leaving 112.6 g (1.09 mole, 78%) clear liquid.
4-Nitro-2,2,4-trimethylpentane was prepared as follows: potassium permanganate (380 g, 2.4 mole) was added in portions to t-octyl amine (50 g, 0.4 mole) and MgSO4 ×7H2 O (60 g) in 250 mL H2 O with mechanical stirring. The temperature was maintained below 30° C. with an ice bath. Stirring and cooling was continued for 2.5 hours after which the reaction was allowed to warm to room temperature and stirred for 48 hours. The reaction was filtered and the residue washed with pentane. The organic layer was separated, dried over MgSO4 and pentane distilled at atmospheric pressure. The product was distilled at <1 mm to give 30 g (47%) of clear liquid.
t-Octyl hydroxylamine was prepared as follows: 4-nitro-2,2,4-trimethylpentane (10.35 g, 0.065 mole) with NH4 Cl (3.49 g, 0.065 mole) was cooled in 75% THF/H2 O with stirring by a magnetic stir bar to 10° C. and zinc (25.5 g, 0.39 mole) added in portions to maintain the temperature at 10°-15° C. (one hour). Reaction was allowed to warm to room temperature and stirred for one hour. The mixture was filtered and the solvent stripped leaving 9.25 g (98%) clear liquid. The hydroxylamine was used immediately in subsequent reactions.
Example 4
Procedure for the synthesis of 2,6-dimethyl-4-(N tert-octyl) nitronyl phenol (DMONP) is similar to other 4-nitronylphenols. t-Octyl hydroxylamine (4.35 g, 0.03 mole) and 3,5-dimethyl-4-hydroxybenzaldehyde (2.25 g, 0.015 mole) were refluxed in 60 mL benzene with 5 mg pTsOH for 15 hours. TLC on silica gel (20% EtOAc/hexane) showed 1:1 aldehyde (rf=0.47) to nitrone (rf=0.29). t-Octyl hydroxylamine (4.35 g, 0.03 mole) was added and the reaction stirred for 18 hours. TLC showed no aldehyde, mostly nitrone, and a few less polar impurities. The solvent was stripped, the residue applied to a silica gel column, and product eluted with mixtures of hexane/EtOAc to give 3.74 g (90%) crystals with a melting point of 113°-114° C.
Example 5
2,6-di-tert-butyl-4-(N-tert-octyl) nitronyl phenol (DBONP) can be prepared as follows. t-Octyl hydroylamine and 3,5-di-tert-butyl-4-hydroxybenzaldehyde are refluxed in benzene with p-TsOH for sufficient time to begin the reaction. t-Octyl hydroylamine can then be added and the reaction stirred until complete reaction has occurred. The solvent is then stripped, the residue applied to a silica gel column, and product eluted with mixtures of hexane/EtOAc which should produce DBONP crystals with a melting point of 153°-154° C.
Example 6
N-tert-octyl C-phenyl nitrone (OPN) can be prepared as follows: t-octyl hydroxylamine and 4-hydroxybenzaldehyde should be refluxed in benzene with p-TsOH for sufficient time to begin the reaction. Additional t-octyl hydroxylamine can be added and the reactants stirred until completion of the reaction. The solvent can then be stripped, the residue applied to silica gel column and product eluted with mixture of hexane/EtOAc which should give OPN crystals.
While the invention has been described by several specific examples, it will be understood that the invention is not limited to the specific examples herein.

Claims (5)

We claim:
1. A compound according to the formula: ##STR25##
2. A pharmaceutical composition comprising a pharmacologically effective amount of a compound as claimed in claim 1, and a pharmaceutically acceptable carrier. .Iadd.3. A pharmaceutical composition comprising a pharmacologically effective amount of 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol and a pharmaceutical vehicle suitable for administration to a patient. .Iaddend..Iadd.4. The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for oral administration to a patient. .Iaddend..Iadd.5. The pharmaceutical composition of claim 4 wherein the vehicle comprises a fat-soluble substance. .Iaddend..Iadd.6. The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for intravenous
administration to a patient. .Iaddend..Iadd.7. The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for subcutaneous administration to a patient. .Iaddend..Iadd.8. The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for intraperitoneal administration to a patient. .Iaddend..Iadd.9. The pharmaceutical composition of claim 3 wherein the pharmaceutical vehicle is a vehicle suitable for topical administration to a patient. .Iaddend..Iadd.10. The pharmaceutical composition of claim 3 wherein the pharmacologically effective amount is an amount providing a dosage of between about 25 to about 250 milligrams of 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol per kilogram of patient body weight. .Iaddend..Iadd.11. A method for treating a medical condition associated with free radicals comprising administering to a patient suffering from said condition an effective, free radical-quenching dosage of 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol.
.Iaddend..Iadd.12. A method for preventing a medical condition associated with free radicals comprising administering to a patient susceptible to said condition an effective, free radical-quenching dosage of 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol. .Iaddend..Iadd.13. The method of claim 11 or 12 wherein the 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol is administered systematically. .Iaddend..Iadd.14. The method of claim 13 wherein the 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol is administered orally. .Iaddend..Iadd.15. The method of claim 13 wherein the 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol is administered intravenously. .Iaddend..Iadd.16. The method of claim 13 wherein the 2,6-di-tert-butyl-4-(N-tert-butyl) nitronyl phenol is administered topically. .Iaddend..Iadd.17. The method of claim 13 wherein said free radicals are the result of inflammation effects. .Iaddend..Iadd.18. The method of claim 13 wherein said free radicals are the result of septic shock. .Iaddend..Iadd.19. The method of claim 13 wherein said free radicals are the result of ischemia/reperfusion.
.Iaddend..Iadd.20. The method of claim 13 wherein said free radicals are the result of liver edema septic shock. .Iaddend..Iadd.21. The method of claim 13 wherein said free radicals are the result of liver edema fatigue stress. .Iaddend.
US08/942,494 1993-10-22 1997-10-02 Spin trap nitronyl hindered phenols Expired - Lifetime USRE36594E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/942,494 USRE36594E (en) 1993-10-22 1997-10-02 Spin trap nitronyl hindered phenols

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/141,241 US5455272A (en) 1993-10-22 1993-10-22 Spin trap nitronyl hindered phenols
US08/942,494 USRE36594E (en) 1993-10-22 1997-10-02 Spin trap nitronyl hindered phenols

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/141,241 Reissue US5455272A (en) 1993-10-22 1993-10-22 Spin trap nitronyl hindered phenols

Publications (1)

Publication Number Publication Date
USRE36594E true USRE36594E (en) 2000-02-29

Family

ID=22494820

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/141,241 Ceased US5455272A (en) 1993-10-22 1993-10-22 Spin trap nitronyl hindered phenols
US08/419,157 Expired - Lifetime US5527828A (en) 1993-10-22 1995-04-10 Spin trap nitronyl hindered phenols
US08/419,159 Expired - Lifetime US5532277A (en) 1993-10-22 1995-04-10 Spin trap nitronyl hindered phenols
US08/942,494 Expired - Lifetime USRE36594E (en) 1993-10-22 1997-10-02 Spin trap nitronyl hindered phenols

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/141,241 Ceased US5455272A (en) 1993-10-22 1993-10-22 Spin trap nitronyl hindered phenols
US08/419,157 Expired - Lifetime US5527828A (en) 1993-10-22 1995-04-10 Spin trap nitronyl hindered phenols
US08/419,159 Expired - Lifetime US5532277A (en) 1993-10-22 1995-04-10 Spin trap nitronyl hindered phenols

Country Status (6)

Country Link
US (4) US5455272A (en)
EP (1) EP0724565B1 (en)
AU (1) AU696451B2 (en)
DE (1) DE69420146T2 (en)
ES (1) ES2136209T3 (en)
WO (1) WO1995011227A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194461B1 (en) * 1996-09-26 2001-02-27 Sumitomo Pharmaceuticals Co., Ltd. Nitrone derivatives
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20050215646A1 (en) * 2004-03-09 2005-09-29 Renovis, Inc. Methods for treating multiple sclerosis and pharmaceutical compositions therefor
WO2012092575A1 (en) 2010-12-30 2012-07-05 Perricone Nicholas V Topical nitrone spin trap compositions for psoriasis
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
PT1288203E (en) * 1995-09-11 2005-08-31 Aventis Pharma Inc CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AU721531B2 (en) * 1996-04-23 2000-07-06 Renovis, Inc. Compositions comprising a nitrone compound for use in treating ocular inflammation
US6376540B1 (en) * 1996-07-19 2002-04-23 Centaur Pharmaceuticals, Inc. Furan nitrone compounds
MA26553A1 (en) 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc ALPHA-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CA2318555A1 (en) * 1998-01-16 1999-07-22 Yong-Kang Zhang Thiophene nitrone compounds
EP1047683A1 (en) * 1998-01-16 2000-11-02 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
CA2333190A1 (en) * 1998-05-19 1999-11-25 Beverly Greenwood-Van Meerveld Furan nitrone therapeutics for the treatment of inflammatory bowel disease
EP1077694B1 (en) * 1998-05-19 2004-07-21 Renovis, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
WO1999059569A1 (en) 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
FR2780404B1 (en) * 1998-06-26 2001-04-13 Adir NOVEL NITRONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE69917643T2 (en) * 1998-07-17 2004-10-07 Renovis Inc ALPHA- (2-HYDROXYPHENYL) NITRONE, THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE FOR TREATING INFLAMMATION
UA66401C2 (en) * 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
IT1312537B1 (en) * 1999-04-16 2002-04-22 Euphar Group Srl DERIVATIVES OF (-) - VERBENONE.
WO2002065993A2 (en) * 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
FR2846968B1 (en) * 2002-11-08 2005-02-04 Salles Jean Pierre NOVEL AMPHIPHILIC DERIVATIVES OF ALPHA-C-PHENYL-N-TERT-BUTYL NITRONE
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
JP4996575B2 (en) 2007-11-15 2012-08-08 ローム アンド ハース カンパニー Nitron manufacturing
ES2367330T3 (en) * 2007-11-15 2011-11-02 Rohm And Haas Company NITRON PREPARATION.
WO2013081778A2 (en) * 2011-11-30 2013-06-06 Angus Chemical Company Nitrone compounds and their use in personal care
EP3114110A1 (en) 2014-03-07 2017-01-11 Dow Global Technologies LLC Nitrone compounds and their use in personal care
EP3142752B1 (en) 2014-05-12 2018-06-20 Dow Global Technologies Llc Nitrone compounds and their use in personal care
US10064804B2 (en) 2014-06-30 2018-09-04 Dow Global Technologies Llc Polymeric nitrones and their use in personal care
CN107427430B (en) * 2015-03-20 2020-12-04 陶氏环球技术有限责任公司 Nitrone inhibition of oxidation of unsaturated fats
US10130574B2 (en) 2015-03-20 2018-11-20 Dow Global Technologies Llc Nitrone inhibition of oxidation of unsaturated fats

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903049A (en) * 1974-01-30 1975-09-02 Goodyear Tire & Rubber Oxidation resistant sulfur curable rubbery polymers
GB2137619A (en) * 1983-03-30 1984-10-10 Gerald Scott Nitrone compounds and stabilised rubber compositions containing them
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
JPH03173861A (en) * 1989-11-30 1991-07-29 Sumitomo Chem Co Ltd Nitron compounds and their production method
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
WO1992022290A1 (en) * 1991-06-18 1992-12-23 Oklahoma Medical Research Foundation Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903049A (en) * 1974-01-30 1975-09-02 Goodyear Tire & Rubber Oxidation resistant sulfur curable rubbery polymers
GB2137619A (en) * 1983-03-30 1984-10-10 Gerald Scott Nitrone compounds and stabilised rubber compositions containing them
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
JPH03173861A (en) * 1989-11-30 1991-07-29 Sumitomo Chem Co Ltd Nitron compounds and their production method
WO1992022290A1 (en) * 1991-06-18 1992-12-23 Oklahoma Medical Research Foundation Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
Black, Shaun, "Membrane Topology of the Mammalian P450 Cytochromes," The FASEB J. 6:680-685, 1992.
Black, Shaun, Membrane Topology of the Mammalian P450 Cytochromes, The FASEB J. 6:680 685, 1992. *
Doba, et al., "α-Tocopherol Decay: Lack of Effect of Oxygen," J. Chem. Soc, Chemical Communication 7:461-462, 1984.
Doba, et al., Tocopherol Decay: Lack of Effect of Oxygen, J. Chem. Soc, Chemical Communication 7:461 462, 1984. *
Druelinger, et al. "Photochemistry of Methylenenitrones and Related Compounds, a Study of Oxaziridine and Nitrene Formation," J. Heterocyclic Chem. 13:1001-1007, 1976.
Druelinger, et al. Photochemistry of Methylenenitrones and Related Compounds, a Study of Oxaziridine and Nitrene Formation, J. Heterocyclic Chem. 13:1001 1007, 1976. *
Forrester, et al., Organic Chemistry of Stable Free Radicals , Academic Press, New York, N.Y. p. 294, 1968. *
Forrester, et al., Organic Chemistry of Stable Free Radicals, Academic Press, New York, N.Y. p. 294, 1968.
Fujii, et al., "Studies on the Superoxide Releasing Site in Plasma Membranes of Neutrophils with ESR Spin-Labels," J. Biochem 108:292-296, 1990.
Fujii, et al., Studies on the Superoxide Releasing Site in Plasma Membranes of Neutrophils with ESR Spin Labels, J. Biochem 108:292 296, 1990. *
Janzen et al., "Locating Spin Traps in Heterogenous Media by 13 C NMR Spectroscopy. Investigations in SDS Micelles, DMPC Vesicles, and Rat Liver Microsomes," J. Org.Chem. 54:2915-2920, 1989.
Janzen et al., Locating Spin Traps in Heterogenous Media by 13 C NMR Spectroscopy. Investigations in SDS Micelles, DMPC Vesicles, and Rat Liver Microsomes, J. Org.Chem. 54:2915 2920, 1989. *
Janzen, et al., "The Reversible Thermal Decomposition of Triphenylmethylperoxy Radical to Triphenylmethyl Radical and Oxygen," J. Am. Chem Soc. 89:1176-1183, 1967.
Janzen, et al., The Reversible Thermal Decomposition of Triphenylmethylperoxy Radical to Triphenylmethyl Radical and Oxygen, J. Am. Chem Soc. 89:1176 1183, 1967. *
Kalyanaraman, et al., "The Spin Trap α-Phenyl N-Tert-Butylnitrone, Inhibits the Oxidative Modifications of Low Density Lipoprotein," FEBS Letters 280:17-20, 1991.
Kalyanaraman, et al., The Spin Trap Phenyl N Tert Butylnitrone, Inhibits the Oxidative Modifications of Low Density Lipoprotein, FEBS Letters 280:17 20, 1991. *
Katsaras, et al., "Location of Two Antioxidants in Oriented Model Membranes. Small-Angle X-Ray Diffraction Study," Biophys J. 59:645-653, 1991.
Katsaras, et al., Location of Two Antioxidants in Oriented Model Membranes. Small Angle X Ray Diffraction Study, Biophys J. 59:645 653, 1991. *
Kosower, Edward, Molecular Biochemistry , McGraw Hill Book Company, Inc., New York, N.Y. p. 168, 1962. *
Kosower, Edward, Molecular Biochemistry, McGraw-Hill Book Company, Inc., New York, N.Y. p. 168, 1962.
Maguire, et al., "Electron Transport Between Cytochrome c and Alpha Tocopherol," Biochemical and Biophysical Research Communications 188:190-197, 1992.
Maguire, et al., Electron Transport Between Cytochrome c and Alpha Tocopherol, Biochemical and Biophysical Research Communications 188:190 197, 1992. *
Pryor et al., "Detection of Free Radicals from Low-Temperature Ozone-Olefin Reactions by ESR Spin-Trapping; Evidence That the Radical Precursor is a Trioxide," J. Am. Chem. Soc. 105:2883-2888, 1983.
Pryor et al., Detection of Free Radicals from Low Temperature Ozone Olefin Reactions by ESR Spin Trapping; Evidence That the Radical Precursor is a Trioxide, J. Am. Chem. Soc. 105:2883 2888, 1983. *
Pryor, William, "Biological Effects of Cigarette Smoke, Wood Smoke, and the Smoke From Plastics: the Use of Electron Spin Resonance," Free Radical Biology & Medicine 13;659-676, 1992.
Pryor, William, Biological Effects of Cigarette Smoke, Wood Smoke, and the Smoke From Plastics: the Use of Electron Spin Resonance, Free Radical Biology & Medicine 13;659 676, 1992. *
Timmins, et al., "Free Radical Formation in Isolated Murine Keratinocytes Treated with Organic Peroxides and its Modulation by Antioxidants," Carcinogenisis 14;1615-1620, 1993.
Timmins, et al., Free Radical Formation in Isolated Murine Keratinocytes Treated with Organic Peroxides and its Modulation by Antioxidants, Carcinogenisis 14;1615 1620, 1993. *
Zahalka, et al., Antioxidant Activity of 1 Thio Tocopherol and Related Compounds. EPR, ENDOR, and UV Visible Absorption Spectra of Some of the Derived Phenoxyl Radicals. J. Org Chem 53;3739 3745, 1988. *
Zahalka, et al., Antioxidant Activity of 1-Thio-α Tocopherol and Related Compounds. EPR, ENDOR, and UV-Visible Absorption Spectra of Some of the Derived Phenoxyl Radicals. J. Org Chem 53;3739-3745, 1988.

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194461B1 (en) * 1996-09-26 2001-02-27 Sumitomo Pharmaceuticals Co., Ltd. Nitrone derivatives
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20050215646A1 (en) * 2004-03-09 2005-09-29 Renovis, Inc. Methods for treating multiple sclerosis and pharmaceutical compositions therefor
WO2012092575A1 (en) 2010-12-30 2012-07-05 Perricone Nicholas V Topical nitrone spin trap compositions for psoriasis
US9034926B2 (en) 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
US9439879B2 (en) 2011-02-28 2016-09-13 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
US9649283B2 (en) 2011-02-28 2017-05-16 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps

Also Published As

Publication number Publication date
ES2136209T3 (en) 1999-11-16
EP0724565B1 (en) 1999-08-18
EP0724565A1 (en) 1996-08-07
WO1995011227A1 (en) 1995-04-27
US5532277A (en) 1996-07-02
DE69420146D1 (en) 1999-09-23
AU696451B2 (en) 1998-09-10
AU8086994A (en) 1995-05-08
US5455272A (en) 1995-10-03
US5527828A (en) 1996-06-18
DE69420146T2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
USRE36594E (en) Spin trap nitronyl hindered phenols
EP0599890B1 (en) Geneserine derivatives as cholinesterase inhibitors
EP0161156A1 (en) 4-Vinylbenzoic-acid derivatives, their preparation and their use as therapeutical compositions and as ligands
FR2501686A1 (en) NOVEL 3,4-DIHYDRO-5H-2,3-BENZODIAZEPINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING SAME
US6051571A (en) Methods for treating medical dysfunctions and diseases using furan nitrone compounds
US5972977A (en) Ophthalmic pharmaceutical compositions comprising a nitrone compound and methods for treating ocular inflammation using such compositions
FR2661909A1 (en) NOVEL THERAPEUTIC HISTAMINE H3 RECEPTOR AGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AS AGONISTS OF THE RECEPTOR AND PROCESS FOR PREPARING THE SAME.
CA2174628C (en) Novel spin trap nitronyl hindered phenols
EP0755917B1 (en) N,N&#39;-di(aralkyl) N,N&#39;-di(carboxyalkyl) alkylen- diamino-derivatives, N-(aralkyl) N&#39;-(carboxyalkyl) N,N&#39;-di(carboxyalkyl) alkylen- diamino-derivatives and N,N&#34;-di(aralkyl)N,N&#39;,N&#34;-tri(carboxyalkyl)dialkylen triamino derivatives and their use in pharmacy and cosmetics
US3459767A (en) Aminomethylindoles
EP0063084A1 (en) Phenethanol amine derivatives, their preparation and use in medicine
WO1996011935A1 (en) Metallocenic diarylethylene derivatives, methods for their preparation and pharmaceutical compositions containing same
KR940000074B1 (en) Pharmacologically active compounds, preparations thereof and uses thereof
EP0082040B1 (en) 3,7a-diazacyclohepta(j,k)fluorene derivatives, their preparation and therapeutical use
EP0022407B1 (en) Cyclophosphathiazenes, process for their preparation and compositions containing them
US3974283A (en) N-substituted-4-T-butyl-1-pyridinethiocarboxamides and their use for treatment of inflammation or pain
EP0389338A1 (en) Platinium complexes, their preparation and pharmaceutical compositions containing them
FR2593501A1 (en) NEW DERIVATIVES BIS (R-OXYIMINO) -5,7 DIHYDRO-6,7 (5H) DIBENZO (A, C) CYCLOHEPTENE, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
EP0675892A1 (en) Novel phosphorus-containing spin-trap compositions
EP0040150A1 (en) Fluoromethylated tyrosine methyl ester
HK1006714B (en) Geneserine derivatives as cholinesterase inhibitors
GB2075977A (en) Methyl 2-fluoromethyl-2- amino-3-(4-hydroxyphenyl) -propionate
FR2491926A1 (en) Raubasine (ajmalicine or delta-yohimbine) anti-anoxic derivs. - used for treat cerebral vascular damage, cerebral sclerosis, cranial trauma disorders and depressive states
PL82401B1 (en) Pyrazole derivatives[ie36778b1]
EP0113600A1 (en) Gamma-butyrolactone derivatives with myocardium protecting and antiarrhytmic activity, process for their preparation and medicines containing them

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 12